ArticleNature and science of sleep2025
Proteome Profiling Identifies CDH2 as a Potential Screening Marker for NAFLD and Liver Fibrosis in the Snoring Population.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Snoring individuals, particularly those with obstructive sleep apnea (OSA), exhibit a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis. The objectives of this study were to explore potential screening biomarkers for NAFLD and liver fibrosis in the snoring population. Methods: The research was carried out as a cross-sectional study at the Sleep Center of the First Affiliated Hospital of Fujian Medical University. All patients underwent FibroScan and overnight polysomnography (PSG). The 96-metabolism related proteins were detected using liquid chromatography-high resolution mass spectrometry (Oink Proteomics). Results: A total of 59 NAFLD were found among the 87 snoring patients. A total of 12 proteins with differential expression levels were identified between non-NAFLD group and NAFLD group via Oink Proteomics. The correlation analysis revealed a close correlation between Cadherin 2 (CDH2) and NAFLD, liver fibrosis (with correlation coefficients of 0.394 and 0.383, respectively, both P < 0.05). The risk of NAFLD and liver fibrosis was much higher in snorers with higher levels of CHD2 compared with snorers with lower levels of CHD2 (both P < 0.05). A combination of CHD2, age, BMI, glucose, AHI and waistline presented the acceptable AUC for the detection of NAFLD and liver fibrosis in snoring patients (0.92, 95% CI: 0.86-0.98 and 0.81, 95% CI: 0.72-0.91, respectively, both p < 0.001). Conclusion: In snoring patients, higher level of CDH2 was identified as a risk factor for NAFLD and liver fibrosis; a combination of CDH2, age, BMI, glucose, AHI and waistline could act as a convenient and effective indicator for screening NAFLD and liver fibrosis. Future research should expand the sample size and conduct multicenter validation to further explore the value of CDH2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.